ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research, and care delivery issues unique to countries and settings with limited health care resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author. Credentialed media can access published articles on the ASCO Publications site using their ASCO.org login information.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.

Publishing April 1, 2024, 4:00 PM ET:

Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1‒2N0M0) Oral Tongue Squamous Cell Carcinoma (Original Report)
Qichun Wei, et al
Request article

Estimating the Impact of Rurality in Disparities in Cancer Mortality (Original Report)
Kelly Kenzik, et al
Request article

Publishing March 29, 2024, 4:00 PM ET:

CONTACT-01: A Randomized Phase 3 Trial of Atezolizumab + Cabozantinib Versus Docetaxel For Metastatic Non-Small Cell Lung Cancer After A Checkpoint Inhibitor and Chemotherapy (Original Report)
Joel Neal, et al
Request article

Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: An International, Multicenter, Retrospective Study (Original Report)
Adam Kittai, et al
Request article

A Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors (Original Report)
Sheila Garland, et al
Request article

Publishing March 28, 2024, 4:00 PM ET:

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials (Original Report)
Demetris Papamichael, et al
Request article

Early Onset Colorectal Cancer (EOCRC) in Egypt: Pathological Characterization, Patterns of Care and Survival Compared to Average Age Onset Colorectal Cancer: A Retrospective Multicentre Cohort Study (Original Report)
Noha Rashad, et al
Request article

Association Between Cervical Inflammatory Mediators and Revalent Cervical HPV Infection (Original Report)
Sally Nneoma Adebamowo, et al
Request article

Human Epidermal Growth Factor Receptor 2–Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population (Original Report)
Katarzyna Joanna Jerzak, et al
Request article

Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma (Original Report)
Milind Javle, et al
Request article

Pyroptosis-Derived Long Noncoding RNA Profiles Reveal a Novel Signature for Evaluating the Prognosis of Patients With Lung Adenocarcinoma (Original Report)
Xinwei Han, et al
Request article

Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer (Original Report)
Shilpa Gupta, et al
Request article

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer (Special Article)
Alexander Wyatt, et al
Request article

Published March 27, 2024, 4:00 PM ET:

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study (Original Report)
Miguel Martin, et al
Request article

Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 (Original Report)
Joseph Unger, et al
Request article

Published March 26, 2024, 4:00 PM ET:

International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma (Original Report)
Michael Binkley, et al
Request article

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810 (Original Report)
Leonard Joseph Appleman, et al
Request article

Failing Forward in Peripheral T-Cell Lymphoma (Editorial)
Steven Horwitz, et al
Request article

Toward Racial Equity in Lung Cancer Screening Eligibility (Editorial)
Hasmeena Kathuria, et al
Request article

Can Machine Learning Predict Favorable Outcome After Radiofrequency Ablation of Hepatocellular Carcinoma? (Original Report)
Amr Muhammed, et al
Request article

Published March 22, 2024, 4:00 PM ET:

The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life (Original Report)
Aditya Bardia, et al
Request article

Recently published Journal articles are featured on the homepage of each ASCO Journal website. Credentialed media can directly access these articles using their Media HQ login information on the Journal website. You will only need to log in once to access content for all ASCO Journals:

To apply for ASCO media credentials or renew your credentials, visit ASCO’s Media Headquarters and click “Create Account” or log in with your existing account information. To request your username or reset your password, click “Need Help. After submitting the required documentation, you will receive an email notification once your media credentials are approved. Your access to Journal articles will be activated within one week of approval. As you await access, once you have received notification of approved media credentials, submit your requested articles to Journal Request to receive them by email. 

The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.